BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23417225)

  • 1. Assessment of FDG retention differences between the FDG-avid benign pulmonary lesion and primary lung cancer using dual-time-point FDG-PET imaging.
    Kaneko K; Sadashima E; Irie K; Hayashi A; Masunari S; Yoshida T; Omagari J
    Ann Nucl Med; 2013 May; 27(4):392-9. PubMed ID: 23417225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer.
    Higashi T; Saga T; Nakamoto Y; Ishimori T; Mamede MH; Wada M; Doi R; Hosotani R; Imamura M; Konishi J
    J Nucl Med; 2002 Feb; 43(2):173-80. PubMed ID: 11850481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.
    Christlieb SB; Strandholdt CN; Olsen BB; Mylam KJ; Larsen TS; Nielsen AL; Rohde M; Gerke O; Olsen KE; Møller MB; Kristensen BW; Abildgaard N; Alavi A; Høilund-Carlsen PF
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1824-36. PubMed ID: 27102266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.
    Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J
    Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5.
    Chen CJ; Lee BF; Yao WJ; Cheng L; Wu PS; Chu CL; Chiu NT
    AJR Am J Roentgenol; 2008 Aug; 191(2):475-9. PubMed ID: 18647920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time sensitivity-corrected retention index: an enhanced metabolic index from 18F-FDG PET to differentiate between benign and malignant pulmonary nodules.
    Wong CY; Al-faham Z; Jolepalem P; Wong WW; Thie J
    Nucl Med Commun; 2014 Dec; 35(12):1220-3. PubMed ID: 25171440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fluorine-18 fluorodeoxyglucose uptake in patients with benign pulmonary nodules].
    Yu CH; Wang T; Sun YE; Yao SL; Tian JH; Yin DY
    Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(2):90-2. PubMed ID: 16620664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ¹⁸FDG PET for grading malignancy in thymic epithelial tumors: significant differences in ¹⁸FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study.
    Nakajo M; Kajiya Y; Tani A; Yoneda S; Shirahama H; Higashi M; Nakajo M
    Eur J Radiol; 2012 Jan; 81(1):146-51. PubMed ID: 20810231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
    Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
    J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area.
    Sathekge MM; Maes A; Pottel H; Stoltz A; van de Wiele C
    S Afr Med J; 2010 Sep; 100(9):598-601. PubMed ID: 20822650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
    Shinya T; Rai K; Okumura Y; Fujiwara K; Matsuo K; Yonei T; Sato T; Watanabe K; Kawai H; Sato S; Kanazawa S
    Clin Nucl Med; 2009 Apr; 34(4):216-21. PubMed ID: 19300050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.
    Mamede M; Higashi T; Kitaichi M; Ishizu K; Ishimori T; Nakamoto Y; Yanagihara K; Li M; Tanaka F; Wada H; Manabe T; Saga T
    Neoplasia; 2005 Apr; 7(4):369-79. PubMed ID: 15967114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5.
    Macdonald K; Searle J; Lyburn I
    Clin Radiol; 2011 Mar; 66(3):244-50. PubMed ID: 21295203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.